Premium
Serum neuron‐specific/nonneuronal enolase ratio in the diagnosis of neuroblastomas
Author(s) -
Viallard Jean Louis,
Tiget Florence,
Hartmann Olivier,
Lemerle Jean,
Demeocq Franclois,
Malpuech Georges,
Dastugue Bernard
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19881215)62:12<2546::aid-cncr2820621216>3.0.co;2-v
Subject(s) - enolase , neuroblastoma , stage (stratigraphy) , medicine , pathology , cutoff , immunohistochemistry , biology , physics , cell culture , paleontology , quantum mechanics , genetics
Pretreatment samples from 24 children with neuroectodermal tumors (two ganglioneuromas, 22 neuroblastomas) and from 106 others with various tumors were submitted to the enzymatic determination of the serum neuron‐specific enolase (NSE). The enzymatic procedure employed in this study allows the systematic determination of the NSE and of the nonneuronal enolase (NNE), thus permitting the calculation of the ratio of the two enolase components. Like results obtained with other procedures, enzymatic determined serum NSE results were raised in a high proportion of Stage IV neuroblastoma (100%) but elevated values also were found in a considerable number of the other tumors (29.2%) like Wilms' tumor, lymphomas, and soft tissue sarcomas. The use of the NSE/NNE ratio which characterizes NSE elevations originating from relative poor or rich sources of NSE, represents an additional index for improving the specificity of the NSE results in the diagnosis of neuroblastomas. With a cutoff value fixed at 7.5%, the specificity of the test is 85.9%. When this limit is fixed at 15%, the specificity reaches 95.3% whereas 81.8% of the results of Stage IV neuroblastomas are still above this value.